

Barbara JarzÄb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2304299/publications.pdf>

Version: 2024-02-01

211
papers

17,038
citations

30070

54
h-index

15266

126
g-index

220
all docs

220
docs citations

220
times ranked

14835
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60â€‰%mg Per Day Compared with the Cabozantinib Capsule at 140â€‰%mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 515-524.	4.5	9
2	In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3841-3851.	6.4	6
3	The role of thyroid sonographic malignancy risk features when the fine needle aspiration biopsy result is indeterminate. <i>Endokrynologia Polska</i> , 2022, 73, 316-324.	1.0	1
4	Diagnosis and treatment of thyroid cancer in adult patients â€” Recommendations of Polish Scientific Societies and the National Oncological Strategy. 2022 Update [Diagnostyka i leczenie raka tarczycy u chorych dorosÅ‚ych â€” Rekomendacje Polskich Towarzystw Naukowych oraz Narodowej Strategii Onkologicznej. Aktualizacja na rok 2022]. <i>Endokrynologia Polska</i> , 2022, 73, 173-300.	1.0	17
5	Heterogeneity of the Clinical Presentation of the MEN1 LRG_509 c.781C>T (p.Leu261Phe) Variant Within a Three-Generation Family. <i>Genes</i> , 2021, 12, 512.	2.4	2
6	A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotypeâ€”Phenotype Correlations. <i>Frontiers in Endocrinology</i> , 2021, 12, 681013.	3.5	7
7	<i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3228-3238.	3.6	36
8	Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1214-1222.	2.2	4
9	Recent advances in precision medicine for the treatment of medullary thyroid cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 307-315.	0.7	0
10	Stereotactic radiotherapy is a useful treatment option for patients with medullary thyroid cancer. <i>BMC Endocrine Disorders</i> , 2021, 21, 160.	2.2	2
11	Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma â€” Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015. <i>Frontiers in Endocrinology</i> , 2021, 12, 718833.	3.5	1
12	Definitive treatment of Gravesâ€™ disease in children and adolescents. <i>Endokrynologia Polska</i> , 2021, 72, 661-665.	1.0	2
13	<i>BRAF</i> V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. <i>European Journal of Cancer</i> , 2020, 124, 161-169.	2.8	41
14	Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival. <i>Frontiers in Endocrinology</i> , 2020, 11, 571421.	3.5	38
15	Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN). <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 144.	2.7	15
16	TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma. <i>Cancers</i> , 2020, 12, 1597.	3.7	13
17	Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinomaâ€”Do They Exist?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4629.	4.1	5
18	Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2773-2781.	1.6	33

#	ARTICLE	IF	CITATIONS
19	European perspective on the use of molecular tests in the diagnosis and therapy of thyroid neoplasms. <i>Gland Surgery</i> , 2020, 9, S69-S76.	1.1	12
20	Impact of the Tumor Microenvironment on the Gene Expression Profile in Papillary Thyroid Cancer. <i>Pathobiology</i> , 2020, 87, 143-154.	3.8	8
21	The role of postoperative adjuvant radiotherapy in local recurrence risk in medullary thyroid carcinoma. <i>Endocrine Connections</i> , 2020, 9, 1-8.	1.9	3
22	Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. <i>Endocrine Connections</i> , 2020, 9, 489-497.	1.9	17
23	Laparoscopic cortical-sparing adrenal surgery in pheochromocytomas associated with hereditary neoplasia syndromes. <i>Endokrynologia Polska</i> , 2020, 71, 518-523.	1.0	1
24	Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes. <i>Archives of Medical Science</i> , 2020, , .	0.9	0
25	Current status of the prognostic molecular markers in medullary thyroid carcinoma. <i>Endocrine Connections</i> , 2020, 9, R251-R263.	1.9	13
26	Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy. <i>JAMA Network Open</i> , 2019, 2, e198898.	5.9	80
27	Important considerations when choosing pharmacotherapy for Graves' disease in children. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1675-1677.	1.8	1
28	2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. <i>European Thyroid Journal</i> , 2019, 8, 227-245.	2.4	179
29	Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 320-327.	1.0	10
30	Novel <i>TG&#x2D;FGFR1</i> and <i>TRIM33&#x2D;NTRK1</i> transcript fusions in papillary thyroid carcinoma. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 558-566.	2.8	19
31	The Association of SNPs Located in the <i>CDKN2B-AS1</i> and <i>LPA</i> Genes With Carotid Artery Stenosis and Atherogenic Stroke. <i>Frontiers in Neurology</i> , 2019, 10, 1170.	2.4	8
32	European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. <i>Thyroid</i> , 2019, 29, 7-26.	4.5	122
33	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 213-220.	11.4	86
34	Paediatric-onset and adult-onset Graves' disease share multiple genetic risk factors. <i>Clinical Endocrinology</i> , 2019, 90, 320-327.	2.4	14
35	Multiple endocrine neoplasia type 1 in Poland: a two-centre experience. <i>Endokrynologia Polska</i> , 2019, 70, 385-391.	1.0	6
36	Surgical approach to differentiated thyroid cancers (DTC) in children [Specyfika leczenia chirurgicznego zr-nicowanych rak-w tarczycy (ZRT) u dzieci]. <i>Endokrynologia Polska</i> , 2019, 70, 357-366.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Current surgical management in RET mutation carriers [Aktualne postępowanie chirurgiczne u nosicieli mutacji proto-onkogenu RET]. <i>Endokrynologia Polska</i> , 2019, 70, 367-379.	1.0	0
38	Heterogeneity of Thyroid Cancer. <i>Pathobiology</i> , 2018, 85, 117-129.	3.8	117
39	131I INTERNAL CONTAMINATION AND COMMITTED DOSE ASSESSMENT AMONG NUCLEAR MEDICINE MEDICAL PERSONNEL. <i>Radiation Protection Dosimetry</i> , 2018, 179, 275-281.	0.8	6
40	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. <i>Journal of the National Cancer Institute</i> , 2018, 110, 362-370.	6.3	60
41	Radioactive Iodine. , 2018, , 688-692.		0
42	Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 438-445.	1.6	102
43	BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2787-2795.	1.6	58
44	Concentrations of Selected Adipokines, Interleukin-6, and Vitamin D in Patients with Papillary Thyroid Carcinoma in Respect to Thyroid Cancer Stages. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-7.	1.5	23
45	Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2647.	4.1	37
46	Medullary Carcinoma. <i>Endocrinology</i> , 2018, , 589-627.	0.1	0
47	Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 783-793.	3.1	42
48	Transcriptomic population markers for human population discrimination. <i>BMC Genetics</i> , 2018, 19, 54.	2.7	3
49	Thyroid and Irradiation. , 2018, , 539-544.		1
50	Rekomendacje Polskich Towarzystw Naukowych –Diagnostyka i leczenie raka tarczycy– Aktualizacja na rok 2018. <i>Endokrynologia Polska</i> , 2018, 69, 34-74.	1.0	32
51	Odróżnienie brodawkowego raka tarczycy od tkanki nienowotworowej w oparciu o profilowanie lipidów metodą... MALDI-MSI. <i>Endokrynologia Polska</i> , 2018, 69, 2-8.	1.0	24
52	Terapia radioizotopowa 131-MIBG złośliwych guzów chromochłonnych i przyzwojaków – badanie jednorodkowe. <i>Endokrynologia Polska</i> , 2018, 69, 246-251.	1.0	11
53	Medullary Carcinoma. <i>Endocrinology</i> , 2018, , 1-39.	0.1	0
54	Endocrine complications of cancer immunotherapy. <i>Endokrynologia Polska</i> , 2018, 69, 722-733.	1.0	5

#	ARTICLE	IF	CITATIONS
55	Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations. <i>Scientific Reports</i> , 2017, 7, 42074.	3.3	16
56	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3241-3250.	3.6	80
57	Advances in small molecule therapy for treating metastatic thyroid cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1049-1060.	1.8	16
58	Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes <i>SDHA</i> , <i>TMEM127</i> , <i>MAX</i> , and <i>SDHAF2</i> for Gene-Informed Prevention. <i>JAMA Oncology</i> , 2017, 3, 1204.	7.1	149
59	Managing tyrosine kinase inhibitors side effects in thyroid cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 117-127.	2.4	13
60	Dynamic risk stratification in the follow-up of thyroid cancer: what is still to be discovered in 2017?. <i>Endocrine-Related Cancer</i> , 2017, 24, R387-R402.	3.1	35
61	European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics. <i>European Thyroid Journal</i> , 2017, 6, 115-129.	2.4	127
62	Gender-dependent and age-of-onset-specific association of the rs11675434 single-nucleotide polymorphism near TPO with susceptibility to Graves' ophthalmopathy. <i>Journal of Human Genetics</i> , 2017, 62, 373-377.	2.3	14
63	Papillary Thyroid Carcinoma in a Boy with Familial Tuberous Sclerosis Complex Attributable to a TSC2 Deletion – A Case Report. <i>Current Oncology</i> , 2017, 24, 423-428.	2.2	7
64	Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1817.	4.1	34
65	Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1184.	4.1	32
66	Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. <i>Wspolczesna Onkologia</i> , 2017, 2, 115-122.	1.4	12
67	Zalecenia dotyczące postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polskie Towarzystwo Guzów) Tj ETQq1 1 0.7843141rgBT /Overclock 10	1.0	20
68	Nowotwory neuroendokrynne układu i dwunastnicy z uwzględnieniem gastrinoma (zasady postępowania) Tj ETQq0 0 0 rgBT /O	1.0	20
69	Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego – zasady postępowania (rekomendowane przez Polskie Towarzystwo Guzów Neuroendokrynnych). <i>Endokrynologia Polska</i> , 2017, 68, 223-236.	1.0	18
70	Nowotwory neuroendokrynne jelita grubego – zasady postępowania (rekomendowane przez Polskie Towarzystwo Guzów) Tj ETQq0 0 0 rgBT /O	1.0	20
71	Wiek zachorowania i płeć jako czynniki modyfikujące związek polimorfizmów zlokalizowanych na chromosomie 9q22 i 14q13 z rakiem brodawkowym tarczycy. <i>Endokrynologia Polska</i> , 2017, 68, 283-289.	1.0	6
72	Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy. <i>Folia Histochemica Et Cytobiologica</i> , 2017, 54, 202-209.	1.5	7

#	ARTICLE	IF	CITATIONS
73	Differences in Gene-Gene Interactions in Gravesâ€™ Disease Patients Stratified by Age of Onset. PLoS ONE, 2016, 11, e0150307.	2.5	11
74	The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice. European Journal of Endocrinology, 2016, 175, 379-385.	3.7	10
75	Two-miRNA classifiers differentiate mutation-negative follicular thyroid carcinomas and follicular thyroid adenomas in fine needle aspirations with high specificity. Endocrine, 2016, 54, 440-447.	2.3	27
76	Efficacy of lenvatinib in treating thyroid cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 1683-1691.	1.8	11
77	Fosbretabulin tromethamine in the treatment of thyroid cancer. Expert Opinion on Orphan Drugs, 2016, 4, 555-561.	0.8	3
78	Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. British Journal of Clinical Pharmacology, 2016, 81, 1124-1133.	2.4	55
79	Somatic mutation profiling of follicular thyroid cancer by next generation sequencing. Molecular and Cellular Endocrinology, 2016, 433, 130-137.	3.2	36
80	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	3.6	179
81	Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. Expert Review of Clinical Pharmacology, 2016, 9, 69-79.	3.1	27
82	Gene signature of the post-Chernobyl papillary thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1267-1277.	6.4	61
83	EurEAs_Gplex â€™ A new SNaPshot assay for continental population discrimination and gender identification. Forensic Science International: Genetics, 2016, 20, 89-100.	3.1	26
84	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clinical Cancer Research, 2016, 22, 44-53.	7.0	193
85	An internistâ€™s approach to cancer diseases based on the model of thyroid cancer treated with tyrosine kinase inhibitors. Polish Archives of Internal Medicine, 2016, 126, 925-928.	0.4	1
86	Emerging multikinase inhibitors for the treatment of differentiated thyroid cancer: whom to treat?. Translational Cancer Research, 2016, 5, S1340-S1344.	1.0	1
87	CiÄ...gÄ, a stratyfikacja ryzyka w zrÄ³Ä¼nicowanym raku tarczycy (DTC) â€™ stymulowane stÄ™Ä¼enie tyreoglobuliny (Tg) w surowicy, przed leczeniem uzupeÄ,niajÄ...cym radiojodem (RAI), najwaÄ¼niejszym czynnikiem ryzyka nawrotu raka u pacjentÄ³w MO. Endokrynologia Polska, 2016, 67, 2-11.	1.0	20
88	Obraz kliniczny guzÄ³w chromochÄ, onnych u nosicieli mutacji protoonkogenu RET â€™ badanie jednoÄ³rodkowe. Endokrynologia Polska, 2016, 67, 54-58.	1.0	5
89	Diagnostyka i leczenie raka tarczycy. Endokrynologia Polska, 2016, 67, 74-145.	1.0	31
90	Polskie rekomendacje diagnostyki i leczenia zrÄ³Ä¼nicowanego raka tarczycy u dzieci. Endokrynologia Polska, 2016, 67, 628-642.	1.0	22

#	ARTICLE	IF	CITATIONS
91	Klasyfikacja molekularna gruczolaków przysadki: w poszukiwaniu kryteriów przydatnych do badań, wysokoprzepustowych. <i>Endokrynologia Polska</i> , 2016, 67, 148-156.	1.0	3
92	Przypadkowo wykryty guz nadnercza (incydentaloma) u dorosłych – zasady postępowania rekomendowane przez Polskie Towarzystwo Endokrynologiczne. <i>Endokrynologia Polska</i> , 2016, 67, 234-258.	1.0	46
93	Transcriptional profiles of pilocytic astrocytoma are related to their three different locations, but not to radiological tumor features. <i>BMC Cancer</i> , 2015, 15, 778.	2.6	22
94	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. <i>Cancer</i> , 2015, 121, 2749-2756.	4.1	159
95	Impact of SNPs on methylation readouts by Illumina Infinium HumanMethylation450 BeadChip Array: implications for comparative population studies. <i>BMC Genomics</i> , 2015, 16, 1003.	2.8	61
96	The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors. <i>PLoS ONE</i> , 2015, 10, e0132821.	2.5	31
97	Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5075.	4.3	160
98	Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk. <i>Scientific Reports</i> , 2015, 5, 8922.	3.3	23
99	Sorafenib for the treatment of thyroid cancer: an updated review. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 573-583.	1.8	30
100	A registry-based study of thyroid paraganglioma: histological and genetic characteristics. <i>Endocrine-Related Cancer</i> , 2015, 22, 191-204.	3.1	29
101	Drug safety evaluation of lenvatinib for thyroid cancer. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1935-1943.	2.4	14
102	Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer. <i>European Journal of Endocrinology</i> , 2015, 173, 873-881.	3.7	13
103	Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 42-50.	1.6	448
104	A two miRNA classifier differentiates follicular thyroid carcinomas from follicular thyroid adenomas. <i>Molecular and Cellular Endocrinology</i> , 2015, 399, 43-49.	3.2	35
105	Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. <i>Journal of Clinical Oncology</i> , 2015, 33, 6012-6012.	1.6	25
106	BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0143688.	2.5	49
107	Czystość występowania mutacji somatycznych RAS w raku rdzeniastym tarczycy – analiza populacji polskiej. <i>Endokrynologia Polska</i> , 2015, 66, 121-125.	1.0	13
108	Ocena bezpieczeństwa i efektywności leczenia sunitynibem w przerzutowych guzach neuroendokrynych trzustki (NEN G1/G2) w zależności od liczby i rodzaju wcześniejszych linii terapeutycznych – doniesienie wstępne. <i>Endokrynologia Polska</i> , 2015, 65, 472-478.	1.0	1

#	ARTICLE	IF	CITATIONS
109	Association between Polymorphisms in the TSHR Gene and Graves' Orbitopathy. PLoS ONE, 2014, 9, e102653.	2.5	20
110	LanroNET, aÄnon-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors ä€ results of interim analysis. Wspolczesna Onkologia, 2014, 6, 442-447.	1.4	4
111	Novel Genome-Wide Association Studyä€Based Candidate Loci for Differentiated Thyroid Cancer Risk. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2084-E2092.	3.6	41
112	Novel therapies for thyroid cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 2641-2652.	1.8	9
113	miRNAs with the Potential to Distinguish Follicular Thyroid Carcinomas from Benign Follicular Thyroid Tumors: Results of a Meta-analysis. Hormone and Metabolic Research, 2014, 46, 171-180.	1.5	39
114	Analysis options for high-throughput sequencing in miRNA expression profiling. BMC Research Notes, 2014, 7, 144.	1.4	75
115	Gene Expression Analysis in Ovarian Cancer ä€ Faults and Hints from DNA Microarray Study. Frontiers in Oncology, 2014, 4, 6.	2.8	73
116	Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma. Thyroid, 2014, 24, 232-240.	4.5	130
117	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet, The, 2014, 384, 319-328.	13.7	1,295
118	Hepatocytes Response to Interferon Alpha Levels Recorded After Liver Resection. Journal of Interferon and Cytokine Research, 2014, 34, 90-99.	1.2	2
119	Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells. Molecular Cancer, 2014, 13, 160.	19.2	22
120	Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and qualityä€ofä€life assessments. Cancer, 2014, 120, 2694-2703.	4.1	106
121	Outcomes of adrenal-sparing surgery or total adrenalectomy in pheochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncology, The, 2014, 15, 648-655.	10.7	137
122	Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. Molecular and Cellular Endocrinology, 2014, 388, 1-9.	3.2	66
123	Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer. Expert Opinion on Orphan Drugs, 2014, 2, 1331-1340.	0.8	4
124	Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial.. Journal of Clinical Oncology, 2014, 32, 6060-6060.	1.6	14
125	Zalecenia ogÄ³ne dotyczÄ...ce postÄ™powania w nowotworach neuroendokrynych ukÄadu pokarmowego (rekomendowane przez PolskÄ... SieÄ GuzÄ³w Neuroendokrynych). Endokrynologia Polska, 2014, 64, 418-443.	1.0	42
126	Terapia nadczynnoÄci tarczycy jodem promieniotwÄrczym jest bezpieczna u chorych na chorobÄ™ Gravesa i Basedowa z orbitopatiÄ... ä€ badanie prospektywne. Endokrynologia Polska, 2014, 65, 40-45.	1.0	8

#	ARTICLE	IF	CITATIONS
127	Multikinase Inhibitors for the Treatment of Progressive, Metastatic Medullary Thyroid Cancer – An Evolving Paradigm. <i>European Endocrinology</i> , 2014, 10, 145.	1.5	0
128	Introduction to European comments on –Medullary Thyroid Cancer: management guidelines of the American Thyroid Association–. <i>Thyroid Research</i> , 2013, 6, S1.	1.5	1
129	Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers – the role of Ct serum level. <i>Thyroid Research</i> , 2013, 6, S9.	1.5	14
130	Presentation of points of general discussion and voting among the speakers of the European Thyroid Association-Cancer Research Network (ETA-CRN) meeting in Lisbon, 2009, entitled –European comments to ATA medullary thyroid cancer guidelines–. <i>Thyroid Research</i> , 2013, 6, S11.	1.5	4
131	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1493.	7.4	775
132	Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues. <i>BMC Medical Genomics</i> , 2013, 6, 38.	1.5	28
133	Genome-Wide Association Study on Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1674-E1681.	3.6	101
134	Profil ekspresji genów w raku pęskonabłonkowym krtani in vivo przy użyciu mikromacierzy oligonukleotydowych wysokiej gęstości. , 2013, 2, 63-69.		0
135	<i>SRGAP1</i> Is a Candidate Gene for Papillary Thyroid Carcinoma Susceptibility. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E973-E980.	3.6	74
136	Cabozantinib in Progressive Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3639-3646.	1.6	989
137	Association between Age at Diagnosis of Graves' Disease and Variants in Genes Involved in Immune Response. <i>PLoS ONE</i> , 2013, 8, e59349.	2.5	38
138	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4-4.	1.6	23
139	Atypical presentation of invasive pulmonary aspergillosis in a liver transplant recipient. <i>Annals of Transplantation</i> , 2013, 18, 238-242.	0.9	11
140	Unsupervised analysis of follicular thyroid tumours transcriptome by oligonucleotide microarray gene expression profiling. <i>Endokrynologia Polska</i> , 2013, 64, 328-334.	1.0	3
141	Reply to J.-F. Chatal et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 2166-2167.	1.6	0
142	Clinical utility gene card for: multiple endocrine neoplasia type 2. <i>European Journal of Human Genetics</i> , 2012, 20, 3-3.	2.8	4
143	Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 134-141.	1.6	1,295
144	Gene Expression Analysis by DNA Microarray in Papillary and Follicular Differentiated Thyroid Cancer. <i>Medical Radiology</i> , 2012, , 233-244.	0.1	0

#	ARTICLE	IF	CITATIONS
145	Combination Chemotherapy in Advanced Adrenocortical Carcinoma. <i>New England Journal of Medicine</i> , 2012, 366, 2189-2197.	27.0	692
146	Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in Anaplastic thyroid cancer. <i>Surgery</i> , 2012, 152, 1078-1087.	1.9	45
147	Original article Expression of genes FOLR1, BAG1 and LAPT4B in functioning and non-functioning pituitary adenomas. <i>Folia Neuropathologica</i> , 2012, 3, 277-286.	1.2	9
148	A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas. <i>British Journal of Cancer</i> , 2012, 107, 994-1000.	6.4	111
149	Current genetic methodologies in the identification of disaster victims and in forensic analysis. <i>Journal of Applied Genetics</i> , 2012, 53, 41-60.	1.9	110
150	Gene expression signatures and ex vivo drug sensitivity profiles in children with acute lymphoblastic leukemia. <i>Journal of Applied Genetics</i> , 2012, 53, 83-91.	1.9	8
151	An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5508-5508.	1.6	73
152	Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5518-5518.	1.6	17
153	A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5591-5591.	1.6	24
154	Rola medycyny nuklearnej w diagnostyce r ³ Å ¹ / ₄ nicowej Åledzion dodatkowych u chorych po splenektomii. <i>Polski Przegląd Radiologii I Medycyny Nuklearnej</i> , 2012, 77, 68-71.	1.0	12
155	Adjuvant Treatment and Follow Up of Differentiated Thyroid Cancer. <i>Head and Neck Cancer Clinics</i> , 2012, , 125-143.	0.0	0
156	Preoperative Endocrine Management of Differentiated Thyroid Cancer. <i>Head and Neck Cancer Clinics</i> , 2012, , 45-53.	0.0	0
157	Gene expression profile of human thyroid cancer in relation to its mutational status. <i>Journal of Molecular Endocrinology</i> , 2011, 47, R91-R103.	2.5	33
158	Differences in the expression profiles of normal contralateral tissues of papillary thyroid cancer patients exposed and not exposed to the Chernobyl fallout. <i>Medecine Nucleaire</i> , 2011, 35, 327-328.	0.2	0
159	BRCA1-related gene signature in breast cancer the role of ER status and molecular type. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 125-136.	1.8	25
160	Gene Expression Profiles for Radiation-induced Thyroid Cancer. <i>Clinical Oncology</i> , 2011, 23, 282-288.	1.4	25
161	The prognostic value of tumor markers doubling time in medullary thyroid carcinoma - preliminary report. <i>Thyroid Research</i> , 2010, 3, 10.	1.5	30
162	Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. <i>Thyroid Research</i> , 2010, 3, 9.	1.5	53

#	ARTICLE	IF	CITATIONS
163	Positive resources: feeling of hope and life satisfaction in a group of patients treated in childhood because of differentiated thyroid gland cancer. <i>Wspolczesna Onkologia</i> , 2010, 5, 316-320.	1.4	2
164	Locus 1q21 Gene Expression Changes in Atopic Dermatitis Skin Lesions: Deregulation of Small Proline-Rich Region 1A. <i>International Archives of Allergy and Immunology</i> , 2010, 151, 28-37.	2.1	30
165	Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18493-18498.	7.1	36
166	Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. <i>Molecular and Cellular Endocrinology</i> , 2010, 322, 8-28.	3.2	114
167	B-Raf ^{V600E} and thrombospondin-1 promote thyroid cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10649-10654.	7.1	164
168	Thyroid Stimulating Hormone Receptor (TSHR) Intron 1 Variants Are Major Risk Factors for Graves' Disease in Three European Caucasian Cohorts. <i>PLoS ONE</i> , 2010, 5, e15512.	2.5	35
169	Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3794-3801.	1.6	337
170	Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1502-1505.	7.1	311
171	Molecular signature of cell cycle exit induced in human T lymphoblasts by IL-2 withdrawal. <i>BMC Genomics</i> , 2009, 10, 261.	2.8	17
172	Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2009, 266, 1501-1507.	1.6	37
173	13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. <i>Thyroid Research</i> , 2009, 2, 8.	1.5	51
174	NBL1 and anillin (ANLN) genes over-expression in pancreatic carcinoma.. <i>Folia Histochemica Et Cytobiologica</i> , 2009, 47, 249-55.	1.5	46
175	Common SNP in <i>pre-miR-146a</i> decreases mature miR expression and predisposes to papillary thyroid carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7269-7274.	7.1	792
176	Total Thyroidectomy and Adjuvant Radioiodine Treatment Independently Decrease Locoregional Recurrence Risk in Childhood and Adolescent Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2007, 48, 879-888.	5.0	169
177	Perspectives and Limitations of Microarray-Based Gene Expression Profiling of Thyroid Tumors. <i>Endocrine Reviews</i> , 2007, 28, 322-338.	20.1	51
178	Prevalence of <i>RAS</i> Point Mutations in Papillary Thyroid Carcinoma; A Novel Mutation at Codon 31 of K- <i>RAS</i> . <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007, 115, 594-599.	1.2	11
179	GermlineNF1 Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2784-2792.	3.6	126
180	A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. <i>Endocrine-Related Cancer</i> , 2007, 14, 809-826.	3.1	67

#	ARTICLE	IF	CITATIONS
181	Application of Bayesian networks for inferring causeâ€effect relations from gene expression profiles of cancer versus normal cells. <i>Mathematical Biosciences</i> , 2007, 209, 528-546.	1.9	10
182	Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2007, 54, 390.e1-390.e16.	0.8	0
183	Association of NFKB1 -94ins/del ATTG promoter polymorphism with susceptibility to and phenotype of Graves' disease. <i>Genes and Immunity</i> , 2007, 8, 532-538.	4.1	43
184	European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. <i>European Journal of Endocrinology</i> , 2006, 154, 787-803.	3.7	1,804
185	Interaction of HLA-DRB1 Alleles with CTLA-4 in the Predisposition to Graves' Disease: The Impact of DRB1*07. <i>Thyroid</i> , 2006, 16, 447-453.	4.5	27
186	Is there a need to redefine the upper normal limit of TSH?. <i>European Journal of Endocrinology</i> , 2006, 154, 633-637.	3.7	179
187	Meta- and Reanalysis of Gene Expression Profiles of Hot and Cold Thyroid Nodules and Papillary Thyroid Carcinoma for Gene Groups. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1934-1942.	3.6	34
188	Use of Monoclonal Anti-EGFR Antibody in the Radioimmunotherapy of Malignant Gliomas in the Context of EGFR Expression in Grade III and IV Tumors. <i>Hybridoma</i> , 2006, 25, 125-132.	0.4	29
189	rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. <i>Endocrine-Related Cancer</i> , 2005, 12, 49-64.	3.1	154
190	Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. <i>Endocrine-Related Cancer</i> , 2005, 12, 773-803.	3.1	160
191	Association of CD40 Gene Polymorphism (C-1T) with Susceptibility and Phenotype of Graves' Disease. <i>Thyroid</i> , 2005, 15, 1119-1124.	4.5	59
192	Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. <i>European Journal of Endocrinology</i> , 2005, 153, 651-659.	3.7	174
193	Gene Expression Profile of Papillary Thyroid Cancer: Sources of Variability and Diagnostic Implications. <i>Cancer Research</i> , 2005, 65, 1587-1597.	0.9	238
194	Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. <i>European Journal of Endocrinology</i> , 2004, 151, 539-548.	3.7	93
195	Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. <i>European Journal of Endocrinology</i> , 2004, 150, 105-112.	3.7	295
196	RET polymorphisms in codons 769 and 836 are not associated with predisposition to medullary thyroid carcinoma. <i>Cancer Detection and Prevention</i> , 2004, 28, 231-236.	2.1	26
197	Using SVD and SVM methods for selection, classification, clustering and modeling of DNA microarray data. <i>Engineering Applications of Artificial Intelligence</i> , 2004, 17, 417-427.	8.1	34
198	Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1077-1086.	6.4	71

#	ARTICLE	IF	CITATIONS
199	Estimation of Risk of Inherited Medullary Thyroid Carcinoma in Apparent Sporadic Patients. Journal of Clinical Oncology, 2001, 19, 1374-1380.	1.6	91
200	Is there loss or qualitative changes in the expression of thyroid peroxidase protein in thyroid epithelial cancer?. British Journal of Cancer, 2001, 85, 875-880.	6.4	20
201	Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 833-841.	6.4	141
202	Influence of Neurotransmitters on Sexual Differentiation of Brain Structure and Function. Experimental and Clinical Endocrinology and Diabetes, 1991, 98, 99-109.	1.2	17
203	Postnatal treatment of rats with the β_2 -adrenergic agonist salbutamol influences the volume of the sexually dimorphic nucleus in the preoptic area. Brain Research, 1990, 516, 257-262.	2.2	20
204	Postnatal Treatment of Rats with Beta-adrenergic Agonists or Antagonists Influences Differentiation	1.2	5
205	Postnatal treatment of rats with adrenergic receptor agonists or antagonists influences differentiation of sexual behavior. Hormones and Behavior, 1987, 21, 478-492.	2.1	10
206	Adrenergic Influences on Sexual Differentiation of the Rat Brain. Frontiers of Neurology and Neuroscience, 1986, 12, 191-196.	2.8	5
207	Pre- and Postnatal Influence of an Estrogen Antagonist and an Androgen Antagonist on Differentiation of the Sexually Dimorphic Nucleus of the Preoptic Area in Male and Female Rats. Neuroendocrinology, 1986, 42, 443-448.	2.5	97
208	Differentiation of the Sexually Dimorphic Nucleus in the Preoptic Area of the Rat Brain Is Inhibited by Postnatal Treatment with an Estrogen Antagonist. Neuroendocrinology, 1984, 38, 297-301.	2.5	136
209	Immunoreactive calcitonin content in foetal thyroid glands and in placentae of rats. European Journal of Endocrinology, 1984, 105, 567-570.	3.7	4
210	Serotonergic Influences on Sexual Differentiation of the Rat Brain. Progress in Brain Research, 1984, 61, 119-126.	1.4	38
211	CHANGES IN SERUM TSH LEVEL AFTER INTRAVENTRICULAR INJECTION OF VARIOUS NEUROMEDIATORS IN RATS. European Journal of Endocrinology, 1978, 87, 279-282.	3.7	24